Thomas Kerbusch, PhD, is the President of Certara Strategic Consulting. Throughout his career, Thomas greatly enjoyed working with talented scientists to make a real difference in drug development by implementing novel and creative quantitative pharmacology and pharmacometric approaches. This has led to numerous key decisions on the progression of novel drugs through their development, successful regulatory interactions and registrations. Examples are IL-23 Phase 2b dose-selection, letermovir, Phase 3 dose-selection and the successful vorapaxar ACM where he was primary responder for PK/PD, M&S and metabolism.
He also made a mark on various pharmaceutical organizations assuring establishment of innovative quantitative approaches and appropriate associated organizational structures. Examples are integration of M&S capabilities from Organon/Schering-Plough and Merck/MSD upon merger of the companies and subsequently in the rollout of the M&S Network at Merck and the Quantitative Pharmacology & Pharmacometrics department thereafter. Key themes were multi-disciplinary integration of expertise, knowledge, data and methodology to assure a systems-pharmacology approach to model-informed drug development.
Thomas received undergraduate education in Biopharmaceutical Sciences at Leiden University and Georgetown University. He obtained his PhD in Clinical Pharmacology at the Netherlands Cancer Institute. In 2001 he conducted postdoctoral research on PK/PD M&S at Uppsala University, Sweden. Thomas got introduced to implementing M&S in an industry setting at Pfizer, UK, leaving in 2006 as a Director of clinical PK/PD M&S to join Organon in the Netherlands, to lead their PK/PD group. Subsequently Thomas headed the PK/PD and Pharmacometrics group at Schering-Plough (2008-2010) and various leadership roles in Merck/MSD as Executive Director for Modeling & Simulation in Early Stage Development and in Quantitative Pharmacology & Pharmacometrics in the PK/PD & Metabolism department (2010-2014) from the same site in Oss, the Netherlands. He was also part of the management team of the Dutch MSD development site. He has (co-) authored over 35 peer-reviewed publications.